Moser SS, Apter L, Solomon J, Chodick G, et al. Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data. Anticancer Res 2024;44:257-265.
PMID: 38159972